Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2818MR)

This product GTTS-WQ2818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2818MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1418MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ11070MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ529MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ2585MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ2268MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ12745MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ8896MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ3059MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW